-
2023
-
EU Expands Dupixent’s Authorization for Eosinophilic Esophagitis
-
Roche, Boehringer tap biosensor firms for patient studies
-
FDA Grants Accelerated Approval to Eli Lilly’s Jaypirca in Mantle Cell Lymphoma
-
FDA Approves Stemline’s Orserdu for Several Forms of Breast Cancer
-
Cassava Claims Phase 2 Win for Its Alzheimer’s Candidate
-
NICE Recommends Vutrisiran for Transthyretin-Related Amyloidosis
-
Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate
-
US FDA clears Transcenta’s IND for Rett syndrome treatment
-
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
-
FDA Grants Rare Pediatric Disease Designation to OR-449 for Treatment of Adrenocortical Carcinoma